Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405945 | 0.80 | PARP1 (0.49) | PARP1SMN1; SMN2IGF1RPIM1CLK2 | |
| SCHEMBL29694218 | 0.79 | TLR7 (0.44) | MAOATDP1PARP1PDPK1CA12 | |
| SCHEMBL7072625 | 0.79 | SMN1; SMN2 (0.41) | JAK2PARP1PDPK1CA12ALOX15 | |
| SCHEMBL212131 | 0.79 | TLR7 (0.44) | MAOATDP1PARP1PDPK1CA12 | |
| SCHEMBL487415 | 0.79 | ALDH1A1 (0.44) | JAK2PARP1PDPK1CA12ALOX15 | |
| SCHEMBL311169 | 0.79 | JAK2 (0.41) | JAK2PARP1PDPK1CA12ALOX15 | |
| SCHEMBL5528653 | 0.79 | GPR3 (0.48) | JAK2PARP1PDPK1CA12ALOX15 | |
| SCHEMBL9076301 | 0.79 | SMN1; SMN2 (0.41) | JAK2PARP1PDPK1CA12ALOX15 | |
| SCHEMBL5507881 | 0.79 | SMN1; SMN2 (0.41) | JAK2PARP1PDPK1CA12ALOX15 | |
| SCHEMBL1486424 | 0.78 | SMN1; SMN2 (0.40) | JAK2PARP1PDPK1CA12ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080662-B2 | Method of preparing 4-amino-1H-imidazo (4,5-c) quinolines and acid addition salts thereof | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2011-12-20 | — | — | US | claimed |
| US-20100184984-A1 | METHOD OF PREPARING 4-AMINO-1H-IMIDAZO (4,5-C) QUINOLINES AND ACID ADDITION SALTS THEREOF | TARO PHARMACEUTICALS U.S.A. (US) | 2010-07-22 | — | — | US | claimed |
| US-7687628-B2 | Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2010-03-30 | — | — | US | claimed |
| EP-1668010-A2 | METHOD OF PREPARING 4-AMINO-1H -IMIDAZO(4,5- C )QUINOLINES AND ACID ADDITION SALTS THEREOF | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050085500-A1 | Method of preparing 4-amino-1H- imidazo(4,5-c)quinolines and acid addition salts thereof | TARO PHARMACEUTICALS U.S.A., INC. | 2005-04-21 | — | — | US | claimed |
| WO-2005033049-A2 | METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2005-04-14 | — | — | WO | claimed |
| EP-0912565-B1 | PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES | MINNESOTA MINING & MFG (US) | 2004-04-14 | — | — | EP | claimed |
| US-6624305-B2 | Reacting a 6H-imidazo(4,5-c) tetrazolo(1,5-a)quinoline with triphenylphosphine and hydrolyzing | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-23 | — | — | US | claimed |
| US-20030153762-A1 | Process for preparing imidazoquinolinamines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-14 | — | — | US | claimed |
| US-20020188127-A1 | Process for preparing imidazoquinolinamines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-12 | — | — | US | claimed |
| EP-3950687-A1 | INDUSTRIAL METHOD FOR SYNTHESISING IMIQUIMOD FROM QUINOLINE-2,4-DIOL APPLICABLE TO THE PHARMACEUTICAL USE THEREOF | PHV Pharma (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-9326978-B2 | A3 adenosine receptor allosteric modulators | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-03 | — | — | US | disclosed |
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2013-08-01 | — | — | US | disclosed |
| US-8420664-B2 | A3 adenosine receptor allosteric modulators | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-04-16 | — | — | US | disclosed |
| US-8106202-B2 | Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor | FERRER INTERNACIONAL, S.A. (ES) | 2012-01-31 | — | — | US | disclosed |
| US-5037986-A | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0425306-A2 | Process for 1H-imidazo[4,5-c]-quinolines | RIKER LABORATORIES, INC. (US) | 1991-05-02 | — | — | EP | disclosed |
| US-4988815-A | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines | RIKER LABORATORIES, INC. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0389302-A1 | Olefinic 1H-imidazo [4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| EP-0385630-A2 | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals | RIKER LABORATORIES, INC. (US) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085500-A1 | Method of preparing 4-amino-1H- imidazo(4,5-c)quinolines and acid addition salts thereof | PAH, IL4I1, H1-5 | MAOA 74/4885MAOB 245/4885TDP1 2711/4885 |
| US-20100184984-A1 | METHOD OF PREPARING 4-AMINO-1H-IMIDAZO (4,5-C) QUINOLINES AND ACID ADDITION SALTS THEREOF | PAH, IL4I1, H1-5 | MAOA 74/4885MAOB 245/4885TDP1 2711/4885 |
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | MAOA 763/4885MAOB 1395/4885TDP1 1508/4885 |
| US-20020188127-A1 | Process for preparing imidazoquinolinamines | VAT1, QARS1, TALDO1 | MAOA 1127/4885MAOB 1502/4885TDP1 281/4885 |
| US-20030153762-A1 | Process for preparing imidazoquinolinamines | VAT1, QARS1, TALDO1 | MAOA 1127/4885MAOB 1502/4885TDP1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.